Bio Pharma Dive
APRIL 6, 2022
Facing mounting competition to its top-selling drug Eylea, Regeneron is teaming up with ViGeneron to develop a genetic medicine for an inherited retinal disease.
World of DTC Marketing
APRIL 8, 2022
It’s time to stop using worthless online ad metrics. Click-through rates are the most used KPI in marketing, but they are useless. Click-through rates don’t correlate with any meaningful brand metrics. Billions of dollars are “optimized” based on nothing but noise. “One impression’ is one web browser making one server request for one advertisement.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
APRIL 8, 2022
Cambridge, UK, CellCentric, aclinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces the appointments of Kris Frese as Director of Cancer Biology, and Andrew Hughes, who joins the Board as a Non-Executive Director. Both have stellar experience and track records in oncology research and development.
pharmaphorum
APRIL 5, 2022
It’s no secret that digital technologies are playing a significant role when it comes to shaping the next era of healthcare. Necessity accelerated the adoption of new and sophisticated technologies and systems throughout the COVID-19 pandemic, but this seismic shift towards digital health has opened up a gap in education. To successfully navigate the potential of digital technologies in healthcare, attention must be focused on upskilling professionals in the field to equip them with the necessar
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
APRIL 7, 2022
Treatment with Aduhelm would only be covered for patients enrolled in a clinical trial under the policy, which largely follows a draft proposal released in January.
World of DTC Marketing
APRIL 6, 2022
DTC marketing has evolved. Those DTC managers who use the exact roadmap will waste a lot of money when accountability is increasing. Challenges await, and there isn’t one set of guidelines for every product category. Challenge #1 – DIGITAL MARKETING. Pharma companies are increasing digital budgets, but they are wasting too much money because of internal staffing issues and inexperience with online marketing.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Drug Patent Watch
APRIL 5, 2022
This is a guest post by Ray Miller and Megan E. Bowers, Ph.D. at DLA Piper. Ray may be contacted at raymond.miller@dlapiper.com. When it comes to protecting therapeutic assets, I…. The post The value of method of use patent claims in protecting your therapeutic assets appeared first on DrugPatentWatch - Make Better Decisions.
Bio Pharma Dive
APRIL 4, 2022
The Swiss pharma said its plan to merge multiple business units and cut yearly costs by $1 billion is likely to impact jobs, but declined to specify which roles and how many.
World of DTC Marketing
APRIL 5, 2022
The old model of looking at performance in the first six months of product launch isn’t relevant. Today, colossal budget product launches are not returning the same ROI as before. Product launches are going to need to be micro-targeted to specific audiences. What is the definition of a successful pharma product launch? Usually, it’s reaching a certain sales level within a specified time, but that metric is not relevant anymore.
Pharma Mirror
APRIL 7, 2022
Let’s face it, dealing with a terminal illness diagnosis will never be an easy task and there’s not much you can do to mitigate the pain. However, there are a few steps that you can take to make the whole ordeal a bit more manageable for the person diagnosed and those around them. There are a few emotional chapters you’ll need to close as well as some practical matters that you should get out of the way if you are diagnosed with a terminal illness.
Pharma Times
APRIL 8, 2022
Alexion Pharma UK, AstraZeneca’s Rare Disease group, announces the recommendation of its pivotal neurofibromatosis treatment
Bio Pharma Dive
APRIL 7, 2022
The layoffs come after safety concerns led the FDA to rebuff its anemia pill, similar to the agency's spurning of FibroGen's rival drug last year.
pharmaphorum
APRIL 6, 2022
Ensuring that patients remain consistent with their therapies is one of the major challenges facing healthcare, so what if you could make treatment a game? That’s the potential behind game-based digital therapeutics and it’s drawing a lot of interest, finds Ben Hargreaves. The impact of video games on modern culture can be felt by even those that have little or no interest in them.
Pharma Mirror
APRIL 6, 2022
London, ATMPS Ltd/Hataali – the leader in blockchain-based data sharing platforms for advanced therapies – announces it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the use of blockchain technologies in personalised medicines. The company also has applications pending in both Europe and Asia as it looks to cement its technological advantage in the rapidly growing advanced therapy space globally.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
APRIL 6, 2022
A technique developed by the University of Birmingham demonstrates link between patients’ alpha brain waves and responses to pain
Bio Pharma Dive
APRIL 4, 2022
Yescarta, previously cleared only for use in treating late-stage lymphoma, can now be used after initial treatment has failed, a first for the cellular drugs.
pharmaphorum
APRIL 4, 2022
The National Institutes of Health (NIH) is funding a nationwide study in the US to support research on long-COVID, chronic COVID, or as it’s scientifically known, post-acute sequelae of SARS-CoV-2 (PASC) in children. An estimated 10% to 30% of adults who contract COVID-19 suffer from long COVID. Though speciality departments and independent institutions have opened to study chronic COVID in adults, little research has been done to evaluate the long-term effects of the virus on children.
Pharma Mirror
APRIL 6, 2022
GENT, BELGIUM, eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased to announce the relocation of its R&D group to a new and larger site in Gent, Belgium. The upgraded R&D facility is in the Zwijnaarde Science Park, where a cluster of biotech companies are located, and includes state-of-the-art laboratories together with allied services.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Times
APRIL 4, 2022
Investments will enhance the development of lipid systems manufacturing, while also boosting the development of gene therapies
Bio Pharma Dive
APRIL 5, 2022
The 170,000-square-foot plant located in North Carolina can now fulfill its primary function: producing commercial-grade Zolgensma, which has become one of the Swiss pharma's top-selling drugs.
XTalks
APRIL 6, 2022
The personalized ctDNA blood test uses the RaDaR™ assay, a liquid biopsy platform developed by the company Inivata. Photo source: Inivata. Lung cancer is the most common cancer in men and the third most common cancer in women, according to global lung cancer statistics by the World Cancer Research Fund. Around 85 percent of cases are non-small cell lung cancer (NSCLC).
Pharma Mirror
APRIL 6, 2022
New York, Kicking off the season for pharmaceutical professionals to come together digitally (09-27 May, 2022) as well as in-person (17-19 May, 2022). CPHI North America will be held as a SMART event, with three weeks of dedicated pharma learning and partnering. The benefit for the CPHI pharma community, which relies on a widening global supply chain, is that a SMART event format stimulates greater collaboration within the industry.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
APRIL 7, 2022
NICE recommends avelumab as treatment for adults with locally advanced or metastatic urothelial cancer
Bio Pharma Dive
APRIL 6, 2022
About half of eligible Americans haven't received a booster and may be less protected should cases surge. Health officials hope to soon ready an updated shot, but experts on the committee struggled to identify the best approach.
BioPharma Reporter
APRIL 4, 2022
The US FDA has approved Yescarta, Kite's CAR-T cell therapy, for initial treatment in adults with large B-cell lymphoma (LBCL) that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy.
pharmaphorum
APRIL 8, 2022
Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. The Dublin-based pharma is paying $15 million upfront for global rights to Werewolf’s WTX-613, a prodrug of the cytokine interferon alfa-2b, which is still back n preclinical development and due to start its first clinical trials next year.
Pharma Times
APRIL 6, 2022
New Dublin development office will be responsible for paediatric clinical trials for seven products across 18 countries
Bio Pharma Dive
APRIL 4, 2022
The large quantity of digitized healthcare data in the U.S. presents an enormous opportunity to shift dramatically how post-marketing safety studies can and should be conducted.
Intouch Solutions
APRIL 8, 2022
Philanthropy at Intouch has always been a big deal. From raising funds for animal-related charities to helping the folks at our local Ronald McDonald House , to granting a young boy’s wish to visit Disney World, even to shaving our heads to support a good cause … we take giving back seriously. Since 2019, we’ve been partnering with Heart to Heart International to spread the giving further than outside our own doors — helping to provide support for those working on the fro
pharmaphorum
APRIL 6, 2022
2021 was a big year in investment financing for US digital health companies, but there are signs that it may be a high watermark. In the first three months of this year there were 183 deals worth a total of $6 billion, giving an average size per deal of just under $33 million, according to venture fund Rock Health’s latest update on the sector.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
345 
Let's personalize your content